title: Development of hydrophobized alginate hydrogels for the vessel-simulating flow-through cell and their usage for biorelevant drug-eluting stent testing.
abstract: The vessel-simulating flow-through cell (vFTC) has been used to examine release and distribution from drug-eluting stents in an in vitro model adapted to the stent placement in vivo. The aim of this study was to examine the effect of the admixture of different hydrophobic additives to the vessel wall simulating hydrogel compartment on release and distribution from model substance-coated stents. Four alginate-based gel formulations containing reversed-phase column microparticles LiChroprep® RP-18 or medium-chain triglycerides in form of preprocessed oil-in-water emulsions Lipofundin® MCT in different concentrations were successfully developed. Alginate and modified gels were characterized regarding the distribution coefficient for the fluorescent model substances, fluorescein and triamterene, and release as well as distribution of model substances from coated stents were investigated in the vFTC. Distribution coefficients for the hydrophobic model substance triamterene and the hydrophobized gel formulations were up to four times higher than for the reference gel. However, comparison of the obtained release profiles yielded no major differences in dissolution and distribution behavior for both fluorescent model substances (fluorescein, triamterene). Comparison of the test results with mathematically modeled data acquired using finite element methods demonstrated a good agreement between modeled data and experimental results indicating that gel hydrophobicity will only influence release in cases of fast releasing stent coatings.
authors.affiliation: Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Straße 3, 17487, Greifswald, Germany.
authors.forename: Beatrice
authors.initials: B
authors.lastname: Semmling
authors.forename: Stefan
authors.initials: S
authors.lastname: Nagel
authors.forename: Katrin
authors.initials: K
authors.lastname: Sternberg
authors.forename: Werner
authors.initials: W
authors.lastname: Weitschies
authors.forename: Anne
authors.initials: A
authors.lastname: Seidlitz
mesh_terms: D000464:Alginates / Q000737:chemistry*; D054855:Drug-Eluting Stents; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D020100:Hydrogels / Q000737:chemistry*; D057927:Hydrophobic and Hydrophilic Interactions
chemical_list: D000464:Alginates; D006603:Hexuronic Acids; D020100:Hydrogels; D020723:Glucuronic Acid
references.citation: J Control Release. 2012 Aug 10;161(3):918-26
references.pmid: 22642931
references.citation: Biomaterials. 1999 Jan;20(1):45-53
references.pmid: 9916770
references.citation: J Pharm Sci. 1998 Jun;87(6):738-44
references.pmid: 9607952
references.citation: Eur J Pharm Biopharm. 2000 Jul;50(1):27-46
references.pmid: 10840191
references.citation: N Engl J Med. 2003 Oct 2;349(14):1315-23
references.pmid: 14523139
references.citation: Int J Pharm. 2010 Nov 15;400(1-2):74-85
references.pmid: 20816734
references.citation: Science. 2006 Jan 20;311(5759):353-5
references.pmid: 16424332
references.citation: Eur J Pharm Sci. 2009 Jun 28;37(3-4):217-22
references.pmid: 19491008
references.citation: Ann N Y Acad Sci. 2001 Nov;944:62-73
references.pmid: 11797696
references.citation: N Engl J Med. 1994 Aug 25;331(8):496-501
references.pmid: 8041414
references.citation: Rapid Commun Mass Spectrom. 2002;16(16):1548-55
references.pmid: 12203246
references.citation: Catheter Cardiovasc Interv. 2006 Jan;67(1):32-7
references.pmid: 16342216
references.citation: J Pharm Sci. 1997 Jul;86(7):779-85
references.pmid: 9232516
references.citation: J Control Release. 2012 May 10;159(3):332-7
references.pmid: 22366523
references.citation: Adv Drug Deliv Rev. 2002 Jan 17;54(1):3-12
references.pmid: 11755703
references.citation: J Control Release. 2012 Jul 20;161(2):703-12
references.pmid: 22366546
references.citation: J Control Release. 2008 Aug 25;130(1):2-8
references.pmid: 18562035
references.citation: Ann Biomed Eng. 2012 Dec;40(12):2687-96
references.pmid: 22648579
references.citation: N Engl J Med. 2002 Jun 6;346(23):1773-80
references.pmid: 12050336
references.citation: J Control Release. 2006 Mar 10;111(1-2):235-46
references.pmid: 16466824
references.citation: J Control Release. 2012 Jun 28;160(3):459-67
references.pmid: 22465391
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9463-7
references.pmid: 15197278
references.citation: Int J Pharm. 2004 May 19;276(1-2):83-92
references.pmid: 15113617
references.citation: N Engl J Med. 1994 Aug 25;331(8):489-95
references.pmid: 8041413
references.citation: Macromol Biosci. 2006 Aug 7;6(8):623-33
references.pmid: 16881042
references.citation: Eur J Pharm Biopharm. 2011 May;78(1):36-48
references.pmid: 21182943
references.citation: Indian Heart J. 2012 May-Jun;64(3):273-9
references.pmid: 22664810
references.citation: J Control Release. 2012 Apr 10;159(1):27-33
references.pmid: 22269665
references.citation: Eur J Pharm Biopharm. 2004 Nov;58(3):659-65
references.pmid: 15451542
references.citation: J Control Release. 2010 Mar 19;142(3):474-82
references.pmid: 19958804
references.citation: Eur J Pharm Biopharm. 2009 Nov;73(3):331-6
references.pmid: 19686848
references.citation: Am J Cardiol. 1993 May 20;71(14):54D-61D
references.pmid: 8488776
references.citation: J Control Release. 2001 May 14;72(1-3):203-15
references.pmid: 11389999
references.citation: J Control Release. 2009 Aug 4;137(3):224-33
references.pmid: 19376173
references.citation: Biomaterials. 2009 Feb;30(4):632-7
references.pmid: 18990438